- Home
- LTRX vs PROK Comparison
LTRX vs PROK Comparison
Compare LTRX & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRX
- PROK
- Stock Information
- Founded
- LTRX 1989
- PROK 2015
- Country
- LTRX United States
- PROK United States
- Employees
- LTRX N/A
- PROK N/A
- Industry
- LTRX Computer Communications Equipment
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LTRX Telecommunications
- PROK Health Care
- Exchange
- LTRX Nasdaq
- PROK Nasdaq
- Market Cap
- LTRX 106.5M
- PROK 126.8M
- IPO Year
- LTRX 2000
- PROK N/A
- Fundamental
- Price
- LTRX $2.05
- PROK $0.79
- Analyst Decision
- LTRX Strong Buy
- PROK Buy
- Analyst Count
- LTRX 6
- PROK 4
- Target Price
- LTRX $5.83
- PROK $5.00
- AVG Volume (30 Days)
- LTRX 219.1K
- PROK 1.1M
- Earning Date
- LTRX 05-02-2025
- PROK 05-09-2025
- Dividend Yield
- LTRX N/A
- PROK N/A
- EPS Growth
- LTRX N/A
- PROK N/A
- EPS
- LTRX N/A
- PROK N/A
- Revenue
- LTRX $155,842,000.00
- PROK $76,000.00
- Revenue This Year
- LTRX N/A
- PROK N/A
- Revenue Next Year
- LTRX $11.33
- PROK N/A
- P/E Ratio
- LTRX N/A
- PROK N/A
- Revenue Growth
- LTRX 12.96
- PROK N/A
- 52 Week Low
- LTRX $1.91
- PROK $0.46
- 52 Week High
- LTRX $4.55
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- LTRX 32.15
- PROK 45.47
- Support Level
- LTRX $1.99
- PROK $0.65
- Resistance Level
- LTRX $2.14
- PROK $1.18
- Average True Range (ATR)
- LTRX 0.16
- PROK 0.17
- MACD
- LTRX 0.00
- PROK 0.03
- Stochastic Oscillator
- LTRX 21.21
- PROK 45.97
About LTRX Lantronix Inc.
Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The IoT System Solutions segment is the key revenue driver for the company. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic markets are the Americas, Europe, the Middle East and Africa, and Asia Pacific Japan. The Americas contribute the vast majority of total revenue.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.